Abvc biopharma receives taiwanese patent for its treatment of major depressive disorder (mdd)

The company holds a us patent for the same treatment fremont, ca, oct. 09, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a taiwanese patent, application no. 109130285, for the use of pdc-1421, a radix polygala (polygala tenuifolia willd) extract, which is used in the company's asset abv-1504 for the treatment of major depressive disorder (mdd).
ABVC Ratings Summary
ABVC Quant Ranking